0.80
+0.0367(+4.83%)
Currency In USD
| Previous Close | 0.76 |
| Open | 0.75 |
| Day High | 0.83 |
| Day Low | 0.74 |
| 52-Week High | 1.7 |
| 52-Week Low | 0.62 |
| Volume | 487,548 |
| Average Volume | 546,892 |
| Market Cap | 41.25M |
| PE | -1.14 |
| EPS | -0.7 |
| Moving Average 50 Days | 0.71 |
| Moving Average 200 Days | 0.8 |
| Change | 0.04 |
If you invested $1000 in Xilio Therapeutics, Inc. (XLO) since IPO date, it would be worth $49.74 as of September 29, 2025 at a share price of $0.796. Whereas If you bought $1000 worth of Xilio Therapeutics, Inc. (XLO) shares 3 years ago, it would be worth $273.51 as of September 29, 2025 at a share price of $0.796.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
GlobeNewswire Inc.
Sep 09, 2025 11:30 AM GMT
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
GlobeNewswire Inc.
Jun 10, 2025 8:30 PM GMT
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
GlobeNewswire Inc.
Jun 05, 2025 10:38 PM GMT
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutiv